Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Opioid Agonist Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder

NCT03745339
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional

Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons

NCT06999811
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy
Interventions
Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR), Medication monitoring (control)
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Terminated Not applicable Interventional

Distress Tolerance for Benzodiazepine Discontinuation

NCT05250570
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), Relaxation Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Wilkinsburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 9, 2026, 4:32 PM EDT
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2010 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

NCT02475447
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

NCT04571619
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Marijuana and Opioids

NCT05485012
View directory record Official record
Conditions
Marijuana Use, Opioid Use
Interventions
Marijuana, Opioid
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Better Options for Chronic Cancer Pain

NCT06574009
View directory record Official record
Conditions
Chronic Pain, Cancer Survivor, Opioid Dependence
Interventions
Multimodal pain care, Medication optimization, Buprenorphine rotation, Opioid tapering
Behavioral · Drug · Device + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis

NCT01195116
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 9, 2026, 4:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

NCT05712707
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
New Haven, Connecticut • Eatontown, New Jersey • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

NCT07800520
View directory record Official record
Conditions
Opioid Use Disorder, OAT
Interventions
[11C]OMAR
Drug
Lead sponsor
Yale University
Other
Eligibility
25 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study

NCT01908062
View directory record Official record
Conditions
Opioid Use Disorder, Alcohol Use Disorder
Interventions
Extended Release Naltrexone, Treatment As usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 9, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional

Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment

NCT07342504
View directory record Official record
Conditions
Alcohol Use Disorder, Opioid Use Disorder, Alcohol Use, Opioid Use
Interventions
Brief opioid-informed alcohol treatment
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Notre Dame, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Pilot Test of a Community-based Buprenorphine Treatment Intervention

NCT01761110
View directory record Official record
Conditions
Opioid Dependence, Injection Drug Use
Interventions
Community-based buprenorphine treatment (CBBT) intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 9, 2026, 4:32 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Oral MG001

NCT07204171
View directory record Official record
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
mitragynine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol in the Treatment of Opioid Use Disorder

NCT06206291
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Withdrawn Phase 2 Interventional

Trifecta Research Study

NCT06810765
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions
Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 9, 2026, 4:32 PM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 9, 2026, 4:32 PM EDT
Active, not recruiting Not applicable Interventional

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

NCT05733442
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Treatment as usual (TAU), CHaRRM-CN
Other
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tahlequah, Oklahoma • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Testosterone Replacement for Male Opioid Agonist Maintained Patients

NCT01873989
View directory record Official record
Conditions
Chronic Pain, Opioid Addiction, Symptomatic Hypogonadism
Interventions
Testosterone replacement, Waitlist control
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 9, 2026, 4:32 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 9, 2026, 4:32 PM EDT
Completed No phase listed Observational

Starting Treatment With Agonist Replacement Therapies Follow-up Study

NCT01592461
View directory record Official record
Conditions
Opioid Dependence
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 9, 2026, 4:32 PM EDT
Withdrawn Phase 4 Interventional

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

NCT04235049
View directory record Official record
Conditions
HCV Infection
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 9, 2026, 4:32 PM EDT